{"transactions":[{"id":746050,"issuer":{"id":3437,"kind":"organization","name":"Quantinuum Inc."},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-08T20:31:39.000Z","date":"2026-06-05","kind":"purchase","planned":false,"acquired":true,"shares":250000,"price":60,"value":15000000.0,"ownership":{"direct":true},"balance_after":255833,"source":{"system":"sec-edgar","filing":"0001628280-26-041630","document":"wk-form4_1780950696.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000162828026041630/wk-form4_1780950696.xml","form_type":"4"}},{"id":746049,"issuer":{"id":3437,"kind":"organization","name":"Quantinuum Inc."},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-06-08T20:31:39.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":5833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of restricted stock units (\"RSUs\"), each of which represents a contingent right to receive one share of Class A Common Stock. The RSUs will vest in three equal annual installments beginning on June 5, 2027."}],"balance_after":5833,"source":{"system":"sec-edgar","filing":"0001628280-26-041630","document":"wk-form4_1780950696.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000162828026041630/wk-form4_1780950696.xml","form_type":"4"}},{"id":4008053,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":63.71,"value":764520.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":23.29,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4008052,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":44.6,"value":535200.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":42.4,"expiration_date":"2026-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4008051,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":12000,"price":27,"value":324000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":60,"expiration_date":"2025-06-11","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4008050,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":75000,"price":80.64,"value":6048000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2024-09-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4008049,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"disposition_to_issuer","acquired":false,"shares":3780,"price":87,"value":328860.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"date","element":"transactionDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In accordance with their terms, RSUs held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such RSU and (ii) $87.00."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4008048,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-03-07T23:14:01.000Z","date":"2018-03-05","kind":"other","acquired":false,"shares":100000,"price":87,"value":8700000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 21, 2018, Juno Therapeutics, Inc. (the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Celgene Corporation (\"Parent\"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent (\"Purchaser\"). On March 5, 2018, Purchaser irrevocably accepted for payment and  promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the \"Merger\") and becoming a wholly-owned subsidiary of Parent."},{"field":"date","element":"transactionDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes."}],"balance_after":3780,"source":{"system":"sec-edgar","filing":"0001209191-18-017798","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118017798/doc4.xml","form_type":"4"}},{"id":4102926,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-01-10T02:02:44.000Z","date":"2018-01-05","kind":"grant","acquired":true,"shares":336,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":103780,"source":{"system":"sec-edgar","filing":"0001209191-18-003053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919118003053/doc4.xml","form_type":"4"}},{"id":4190200,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-06T23:26:40.000Z","date":"2017-10-05","kind":"grant","acquired":true,"shares":361,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":103444,"source":{"system":"sec-edgar","filing":"0001209191-17-056349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919117056349/doc4.xml","form_type":"4"}},{"id":4260818,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-07-07T23:47:24.000Z","date":"2017-07-05","kind":"grant","acquired":true,"shares":516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":103083,"source":{"system":"sec-edgar","filing":"0001209191-17-044459","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919117044459/doc4.xml","form_type":"4"}},{"id":4277353,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-19T20:32:56.000Z","date":"2017-06-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option become vested and exercisable on the earlier of (i) the date of the 2018 Annual Meeting of Stockholders and (ii) the first anniversary of the grant date, in either event, subject to the director continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan) through such date."}],"balance_after":12000,"derivative":{"exercise_price":23.29,"expiration_date":"2027-06-15","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-040835","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919117040835/doc4.xml","form_type":"4"}},{"id":4356758,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-06T20:47:04.000Z","date":"2017-04-05","kind":"grant","acquired":true,"shares":698,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":102567,"source":{"system":"sec-edgar","filing":"0001209191-17-026102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919117026102/doc4.xml","form_type":"4"}},{"id":4495081,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-01-09T22:04:20.000Z","date":"2017-01-05","kind":"grant","acquired":true,"shares":768,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":101869,"source":{"system":"sec-edgar","filing":"0001209191-17-002963","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919117002963/doc4.xml","form_type":"4"}},{"id":4578963,"issuer":{"id":168572,"kind":"organization","name":"Juno Therapeutics, Inc.","symbol":"JUNO"},"owners":[{"id":40445,"kind":"person","name":"Barron Hal","position":1,"cik":"0001418677","reported_name":"Barron Hal","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-18T00:37:29.000Z","date":"2016-10-05","kind":"grant","acquired":true,"shares":438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of fully vested restricted stock units."}],"balance_after":101101,"source":{"system":"sec-edgar","filing":"0001209191-16-146106","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1418677/000120919116146106/doc4.xml","form_type":"4"}}]}